Abstract: Carbapenem antibiotics are the most effective antimicrobials for the treatment of infections caused by the most resistant bacteria. They belong to the category of β-lactams that include the penicillins, cephalosporins, monobactams and carbapenems. This class of antimicrobials has a broader spectrum of activity than most other β-lactams antibiotics and are the most effective against Gram-positive and Gram-negative bacteria. All β-lactams antibiotics have a similar molecular structure: the carbapenems together with the β-lactams. This combination gives an extraordinary stability to the molecule against the enzymes inactivating the β-lactams. They are safe to use and therefore widespread use in many countries has given rise to carbapenem resistance which is a major global public health problem. The carbapenem resistance in some species is intrinsic and consists of the capacity to resist the action of antibiotics with several mechanisms: for the absence of a specific target, or an intrinsic difference in the composition of cytoplasmatic membrane or the inability to cross the outer membrane. In addition to intrinsic resistance, bacteria can develop resistance to antibiotics with several mechanisms that can be gathered in three main groups. The first group includes antibiotics with poor penetration into the outer membrane of bacterium or antibiotic efflux. The second includes bacteria that modify the target of the antibiotics through genetic mutations or post-translational modification of the target. The third includes bacteria that act with enzyme-catalyzed modification and this is due to the production of beta-lactamases, that are able to inactivate carbapenems and so called carbapenemases. In this review, we focus on the mode of action of carbapenem and the mechanisms of carbapenem resistance.

Keywords: β-lactams antibiotics; carbapenem antimicrobials; antibiotic resistance; infections

1. Introduction

Carbapenem antibiotics are considered the first line of treatment for infections caused by the most resistant bacteria such as: *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacteriaceae*, (*Klebsiella pneumonia*, *Escherichia coli*, *Enterobacter* spp., *Serratia* spp., *Proteus* spp.,), *Enterococcus faecium*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Shigella* spp. and *Mycobacterium tuberculosis*. The worldwide development of antibiotic resistance is considered a serious healthcare problem. In 2017, the World Health Organization (WHO) has given global priority to guide the research and to discover new antibiotics for an issued list of 12 antibiotic-resistant bacteria and particularly for carbapenem-resistant Acinetobacter baumannii (CRAB). These bacteria are part of the ESKAPE group (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *A cinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter species*) which approximately causes more than 2 million people in the United States to be infected with antibiotic-resistant bacteria annually, with 23,000 deaths...
as a direct result 4,5 [1–3]. Carbapenems are beta-lactams antibiotics such as other antibiotic penicillins (cephalosporins and monobactams). They are the most used antibiotics worldwide. All beta-lactams antibiotics have a similar molecular structure: a beta-lactam ring [4–6]. Carbapenem have a penicillin-like five-membered ring, but the sulfur at C-1 in the five-membered ring is replaced by a carbon atom and a double bond between C-2 and C-3 has been introduced [5]. For carbapenems, the characteristic setting of the side chain in the trans position instead of the cis position, commonly found in other beta-lactams, made them insensitive to the effects of beta-lactamases. The PBPs 1a, 1b 2 and 3 are the principal targets of inhibition and PBPs 2 and 3 are specific for Gram-negative bacteria. Beta-lactam antibiotics can kill or even inhibit susceptible bacteria. The concentration of an antibiotic at the site of infection must be sufficient to inhibit the growth of the offending microorganism. If host defenses are impaired, antibiotic-mediated killing may be required to eradicate the infection. The concentration of the drug at the site of infection must not only inhibit the organism, but must also remain below the level that is toxic to human cells. If this can be achieved, the microorganism is considered to be susceptible to the antibiotic. The cell walls of bacteria are essential for their normal growth and development. Peptidoglycan is a heteropolymeric component of the cell wall that provides rigid mechanical stability. Gram-positive bacteria have as many as 40 layers of peptidoglycan, in Gram-negative bacteria, there appears to be only one or two layers. The surface structure in Gram-negative bacteria is more complex and the inner membrane, which is analogous to the cytoplasmic membrane of Gram-positive bacteria, is covered by the outer membrane, lipopolysaccharide and capsule. The outer membrane functions are an impenetrable barrier for some antibiotics. Other pharmacological differences that characterize the two types of bacteria are membrane permeability, efflux pumps, a large amount of different beta-lactamase and the transpeptidation reaction, that occurs outside the cell membrane [5]. It is the last step in peptidoglycan synthesis that is inhibited by the beta-lactam antibiotics [7]. Carbapenems are most effective against many bacterial infections such as salmonellae bacteria, E.Coli, Mycobacterium tuberculosis, Methicillin-resistant Staphilococcus aureus (MRSA), Clostridium difficile, Klebsiella pneumonia and Pseudomonas aeruginosa. They are safe to use and thus they have spread rapidly through all continents (many countries) giving rise to the carbapenem resistance [8]. The carbapenem resistance in some species is intrinsic such as Staphilococcus aureus, Escherichia coli and Pseudomonas aeruginosa and consists of the capacity to resist action of antibiotics with several mechanisms: for the absence of a specific target, or an intrinsic difference in the composition of cytoplasmatic membrane or the inability to cross the outer membrane. In addition to intrinsic resistance, bacteria can develop resistance to antibiotics with several mechanisms that can be assembled in three main groups. The first group includes antibiotics with poor penetration into the outer membrane of bacterium or antibiotic efflux. The second includes bacteria that modify the target of the antibiotics through genetic mutations or post-translational modification of the target. The third includes bacteria that act with enzyme-catalyzed modification.

2. Mechanism of Resistance

2.1. Decreased Permeability

Resistance to beta-lactam drugs may be related to the inability of antibiotics to reach their sites of action by reducing the entry into their outer cell walls through the porin channels. Some small hydrophilic antibiotics such as beta-lactams, as well as tetracycline, chloramphenicol and fluoroquinolones diffuse through aqueous channels in the outer membrane that are formed by proteins (Omp) called porins [9]. The number, the form and quality of porins in the outer membrane are mutable among different Gram-negative bacteria. A significant example is P. aeruginosa which is intrinsically resistant to a wide variety of antibiotics due its reduced classic high-permeability porins' expression. Broader spectrum of beta-lactam antibiotics such as ampicillin and amoxicillin and most of cephalosporins can diffuse through the pores in the E. coli outer membrane more rapidly than penicillin G. These are important instances of bacterial resistance to beta-lactam antibiotics [10,11].
2.2. Overexpression of Efflux Pump

Active efflux pumps serve as another mechanism of resistance, removing the antibiotic from its site of action before it can act. This is an important mechanism of β-lactam resistance in *P. aeruginosa*, *E. coli* and *Neisseria gonorrhoeae*. Multidrug efflux pumps traverse both the inner and outer membranes of Gram-negative bacteria. The pumps are composed of a minimum of three proteins and are energized by the proton motive force and is produced by the respiratory enzymes and oxidative phosphorylation. Increased expression of these pumps is an important cause of antibiotic resistance. The onset of the mechanism of antibiotic resistance may represent a genetic occurrence [12–14]. The mutation responsible for drug resistance is usually a modification at a specific site on bacterial chromosomes. The capture, accumulation and dissemination of resistance genes are largely due to the actions of mobile genetic elements (MGE), a term used to refer to elements that promote intracellular DNA mobility (e.g., from the chromosome to a plasmid or between plasmids) as well as those that enable intercellular DNA mobility [15]. Thus, the resistance can be transferred from a resistant microorganism to a new location in the same or different DNA to a sensitive microorganism [16]. Multidrug efflux pumps are incorporated into bacteria and their purpose is to transport antibiotics outside the outer membrane of bacteria. Moreover, drug-specific efflux mechanism is promoted by plasmids and others mobile transporters [17]. All these components participate in specific activity promoting horizontal genetic exchange and contribute to achieve and disseminate the resistance genes. Bacteria efflux proteins are proteins identified primarily in Gram-negative bacteria but also exist in Gram-positive bacteria. They are divided into seven families. The seven families included in the resistance-nodulation-division (RND) superfamily are: the heavy metal efflux (HME), the nodulation factor export family (NFE), the major facilitator (MF) superfamily, the SecDF protein-secretion accessory protein family, the hydrophobe/amphiphile efflux-2 family, the eukaryotic sterol homeostasis family and the hydrophobe/amphiphile efflux-3 family. The efflux pumps of the RND superfamily, such as AcrB of *E. coli* and MexB of *P. aeruginosa*, play a fundamental role in promoting multidrug resistance. These pumps are associated with outer membrane channel such as TolC of *E. coli* and OprM of *P. aeruginosa* belonging to the OMF family proteins, the AcrA of *E. coli* and MexA of *P. aeruginosa* that are included into the MFP family. These three groups of proteins are essential for drug efflux and the mere lack of one these give the entire system a non-functional status. All these elements are involved in the intercellular mechanism of antibiotic resistance. Efflux mechanism or to be more precise, genes encoding efflux pumps are not commonly transmitted by mobile genetic elements. Only a few plasmid-mediated efflux pumps have been described in recent years. The transcription of genes involved in the efflux pumps is checked by local regulators. The overexpression of efflux genes, that are at the basis of Gram-negative bacteria resistance, is regulated by the mutation mechanism.

2.3. Mutation and Transformation in Antibiotic Target Structures

Another mechanism which can develop antibiotic resistance is represented by the mutation of the antibiotic target. The resistance to streptomycin, to quinolones, to rifampin and others antibiotic groups is caused by a series of mutations that can occur in the gene encoding the target protein, the protein concerned with drug transport and/or with drug activation. [18] The archetypal example of this is penicillin resistance in *S pneumoniae* and which is conferred by mosaic penicillin-binding protein (pBP) genes encoding penicillin-insensitive enzymes. Mosaicism in the penA gene, which encodes a PBP, in *N gonorrhoeae* has also been linked with high-level resistance to extended-spectrum cephalosporins. Every antibiotic has its specific target site, by binding to which exerts its inhibitory effect. Mutation of the target site can occur during an infection and a mutation into a single microorganism can induce resistance [19]. Genes encoding DNA gyrase or topoisomerase IV, within the bacterial chromosomal are responsible for quinolone resistance, this resistance is expanded above all after the therapeutic use of these antibiotics in *Pseudomonas* and *Staphylococci* [20]. The mechanism of mutation may occur in a functional target with a
decreasing affinity for the antibiotics, which do not work completely and behave with a reduced efficiency (Table 1). Another mechanism of bacterial resistance to antimicrobial agents is the transformation. This is the capacity of transferring genetic information, involving uptake and incorporation of DNA, how it happens in altered penicillin-binding proteins (PBPs), that are mosaics of overseas DNA imported and incorporated from a streptococcus to a resident PBP gene [21].

Table 1. Molecular mechanisms of antibiotic resistance.

| ↓ Permeability | Outer membrane forms a permeability barrier (Gram positive >Gram negative). Down-regulation of porins or by the replacement of porins with more selective channels. |
| ↑ Efflux | Bacterial efflux pumps actively transport many antibiotics out of the cell (multidrug resistance [MDR] efflux pumps). |
| Mutation and Transformation in Antibiotic Target Structures | Changes to the target structure that prevent efficient antibiotic binding: Transformation can confer antibiotic resistance by target protein modification through the formation of ‘mosaic’ genes. Acquisition of a gene homologous to the original target. Protection by modification of the target: Erythromycin ribosome methylase (erm). Chloramphenicol–florfenicol resistance (cfr) methyltransferase. Quinolone resistance (qnr) gene. |

2.4. Modification of Antibiotics by the Hydrolysis of the Molecule

The modification of antibiotics by hydrolysis is a major mechanism of antibiotic resistance that has been relevant since the first use of antibiotics, with the discovery of penicillinase (a β-lactamase) in 1940. Afterwards, the β-lactam-hydrolyzing enzymes have broadened their activity from penicillinas, followed by cephalosporinas, then extended to spectrum β-lactam ESBLs and most recently, to the mannose-binding lectine MBLs and other carbapenemases [22]. The MBLs is characterized by the ability to hydrolyze carbapenem (often considered as last resort drugs) and bacteria producing these β-lactamases including A baumannii, K pneumoniae and E.coli render many of the β-lactam class of antibiotics such as penicillinas, cephalosporinas, monobactamins and carbapenemins ineffective [22]. Beta-lactamases are classified into four main groups based on their amino acid sequences (classes A, B, C and D). The production of all four classes of beta-lactamases (A, B, C and D) is generally chromosomally encoded [23,24]. Class A includes extended-spectrum β-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase enzymes; class B enzymes are the metallo- β-lactamases (MBLs) that have a broad substrate range, being able to inhibit all beta-lactam antibiotics except the monobactamins [25]; class C enzymes are the cephalosporinas, broadly disseminated enzymes usually resistant to cephamycins (cefoxitin and cefotetan), penicillins and cephalosporinas [26,27]; and class D enzymes are oxacillinas. Recently it has been recognized that A baumannii, although often considered a less virulent pathogen compared with K. pneumoniae and P. aeruginosa, plays a significant role in spreading broad-spectrum resistance genes to other Gram-negative organisms [28].

The increase in ESBL-producing bacteria has enlarged the clinical use of carbapenemins, as well as increasing the number of carbapenem hydrolyzing activity. These enzymes, known as carbapenemases, are a large variety and were identified for the first time in Enterobacteriaceae and were divided into the Ambler four classes of β-lactamases, class A, B, C and D, and all are characterized by having a part in common of serine in the target. Their function is to inactivate β-lactame antimicrobials and among these mostly carbapenemins [29,30]. The hallmark of these enzymes is the ability to inactivate a broad range of β-lactams, including carbapenemins and extended-spectrum cephalosporinas. Although first identified on the chromosomes of single species, many carbapenemase are now plasmid-
mediated and have been reported in Enterobacteriaceae, *P. aeruginosa* and *A. baumannii* [31]. The spread of carbapenemases has occurred in different ways, as exemplified by the *kpc* and *ndm* genes. The serine carbapenemase KPC was first identified in *K. pneumoniae* in 1996 [32] and has since been described within several species of Enterobacteriaceae [33]. The *kpc* gene is plasmid-borne and is associated with a dominant clone of KPC-producing *K. pneumoniae*, ST258, which is found worldwide [34]. This gene is often carried on the pKP-Q1 plasmid or on closely related variants [35], and there are several variants of the *kpc* gene that encode proteins that can be differentiated by single amino acid substitutions (although most retain similar activity); KPC2- and KPC3-producing strains have been responsible for outbreaks in the United States, Greece, Israel and the United Kingdom [36,37].

2.4.1. Class A Carbapenemases

Class A carbapenemases are chromosomally encoded (SME, NmcA, SFC-1, BIC-1, PenA, FPH-1, SHV-38), plasmid-encoded (KPC, GES, FRI-1), or both (IMI) [27]. Among these, the best known KPC (*Klebsiella pneumoniae* carbapenemase) was spread all around the world and has been isolated in most of the clinical enterobacterial species such as *P. aeruginosa* and *A. baumannii*. Generally, class A carbapenemases reduce susceptibility to imipenem for the bacteria sensitive to it and allow the hydrolysis of a broad variety of β-lactams, including carbapenems [38].

2.4.2. Class B Carbapenemases

The class B of the Ambler group belonging to the (MBLs) are clinically the most relevant carbapenemases. These are divided into three subclasses: B1, B2, and B3, but the largest number of clinically relevant MBLs belong to the B1 subclass, including the most frequently Verona integron-encoded MBL (VIM), imipenemase (IMP) and New Delhi MBL (NDM). Those MBLs are generally located within different integron structures, which are connected with mobile plasmids or transposons facilitating the transfer of resistance genes between bacteria [29].

2.4.3. Class D Carbapenemases

Class D carbapenemases (Oxa-type β-lactamases, CHDLs) are a group of enzymes that have been discovered in *A. baumannii* and *K. pneumoniae* human strains [39]. These carbapenemases and specifically the OXA-48 and related variant are of clinical relevance because they make it difficult to treat infection [12]. In clinical therapy, the β-lactamase inhibitors (i.e., amoxicillin-clavulanic acid etc.) are effective for class A β-lactamases, but do not inhibit class D carbapenemases. Therefore, it is important in the next future to develop inhibitors of *A. baumannii* class D carbapenemases to make the carbapenem antimicrobials effective [29,40] (Table 2).

2.4.4. Class C Carbapenemases

Class C enzymes are not considered carbapenemases. However, it has been shown that they possess a low potential of carbapenem hydrolysis, and their overproduction may contribute to carbapenem resistance combined with diminished outer-membrane permeability or efflux pump overexpression [41].
Table 2. Molecular classification of carbapenemase enzymes.

| Class   | Description                                                                 |
|---------|-----------------------------------------------------------------------------|
| Class A | Chromosomally encoded—NmcA (not metalloenzyme carbapenemase A)             |
|         | - SME (Serratia marcescens enzyme).                                         |
|         | - IMI-1 (Imipenem-hydrolysing β-lactamase).                                |
|         | - SFC-1 (Serratia fonticola carbapenemase-1).                              |
|         | Plasmid encoded                                                             |
|         | - KPC (Klebsiella pneumoniae carbapenemase, KPC-2 to KPC-13). IMI (IMI-1 to IMI-3). |
|         | - GES (Guiana extended spectrum, GES-1 to GES-20).                         |
| Class B | β-lactamases inhibited by EDTA                                             |
|         | - NDM-1 (New Delhi metallo-β-lactamase 1).                                 |
|         | - IMP (Imipenem-resistant Pseudomonas).                                    |
|         | - VIM (Verona integron-encoded metallo-β-lactamase).                       |
|         | - GIM (German imipenemase).                                                 |
|         | - SIM (Seoul imipenemase).                                                  |
| Class C | Emerging class resistant to penicillin, oxyiminocephalosporins, cephamycins |
|         | (cefoxicin and cefotetan), and, variably, to aztreonam.                    |
|         | - ACT (AmpC type).                                                          |
|         | - CMY (Cephamycinase).                                                      |
|         | - ADC (Acinetobacter-derived cephalosporinase).                            |
| Class D | β-lactamases poorly inhibited by EDTA or clavulanic acid                    |
|         | - OXA (Oxacillin-hydrolyzing carbapenemases).                              |

3. Discussion

Therapy with β-lactam antibiotics is dynamic. The prevalence of bacterial resistance to these agents continues to rise, while new and more effective agents are released for clinical use. The effort against infectious diseases is probably one of the greatest public health challenges faced by our society, especially with the emergence of carbapenem-resistant Gram-negative species that are in some cases pan-drug resistant [42]. β-lactam antibiotics are essential and the most prescribed antibiotics that share a common structure and mechanism of action: the inhibition of synthesis of the bacterial peptidoglycan cell wall. Although bacteria can develop resistance to antibiotics, β-lactam antibiotics cannot kill or even inhibit all bacteria and various mechanisms of bacterial resistance to these agents are operative. The bacterial resistance can be caused by the inability of the agent to penetrate to its site of action or by energy-dependent efflux systems for pumping the antibiotics out of the bacteria. Bacteria can also destroy β-lactam antibiotics enzymatically.

Different microorganisms elaborate a number of distinct β-lactamases, although most bacteria produce only one form of enzyme. In general, Gram-positive bacteria produce a large amount of β-lactamase which is secreted extracellularly. In Gram-negative bacteria, β-lactamases are found in relatively small amounts, but are located in the periplasmic space between the inner and the outer cell membranes. Since the enzymes of cell wall synthesis are on the outer surface of the inner membrane, these β-lactamases are strategically located for maximal of the microbe.

β-lactamases of Gram-negative bacteria are encoded either in chromosomes or in plasmids and these enzymes, together carbapenemases, may hydrolyze a broad variety of β-lactam antibiotics such as penicillins, cephalosporins, aztreonam and carbapenems. Carbapenem have the broadest antimicrobial spectrum of any antibiotic, the main problem is the bacterial resistance against β-lactam antibiotics that continues to increase at a dramatic rate. Many factors are involved, among these are the greater number of relatively resistant microorganisms in a large population, the amount of [43] β-lactamase produced and the phase of growth of the culture.

4. Conclusions

The production of carbapenemases is the major mechanism underlying carbapenem resistance around the world and represents a great health concern. More knowledge is needed to control resistant genes and resistant organisms and their dissemination. There is
an urgent need for a global collaboration to plan valid strategies to prevent the spread of carbapenemases and the development of new antimicrobial molecules.

**Author Contributions:** Conceptualization, C.A. and P.S.; methodology, F.C.; data curation, V.P.; writing—original draft preparation, A.B. and M.B.; writing—review and editing, L.G.G. and M.B.P.; supervision, M.C.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** No applicable.

**Informed Consent Statement:** No applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 2017. Available online: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf (accessed on 1 February 2019).

2. Aslam, B.; Wang, W.; Arshad, M.I.; Khurshid, M.; Muzammil, S.; Nisar, M.A.; Alvi, R.F.; Aslam, M.A.; Qamar, M.U.; Salamat, M.K.F.; et al. Antibiotic resistance: A rundown of a global crisis. *Infect. Drug Resist.* 2018, 11, 1645–1658. Available online: http://www.ncbi.nlm.nih.gov/pubmed/30349322 (accessed on 19 January 2019). [CrossRef] [PubMed]

3. Giacci, L.; Pace, M.; Passavanti, M.; Gargano, F.; Aurilio, C.; Sansone, P. Ceftolozane/Tazobactam for Resistant Drugs *Pseudomonas aeruginosa* Respiratory Infections: A Systematic Literature Review of the Real-World Evidence. *Life* 2021, 11, 474. [CrossRef] [PubMed]

4. Zhanel, G.G.; Wiebe, R.; Dilay, L.; Rubinstein, E.; Hoban, D.J.; Noreddin, A.M.; Karlowsky, J.A. Comparative Review of the Carbapenems. *Drugs* 2007, 67, 1027–1052. [CrossRef] [PubMed]

5. Silhavy, T.J.; Kahne, D.; Walker, S. The bacterial cell envelope. *Cold Spring Harb Perspect Biol* 2010, 2, a000414. [CrossRef] [PubMed]

6. Van Dam, V.; Olrichs, N.; Breukink, E. Specific Labeling of Peptidoglycan Precursors as a Tool for Bacterial Cell Wall Studies. *ChemBioChem* 2009, 10, 617–624. [CrossRef]

7. Papp-Wallace, K.M.; Endimiani, A.; Taracila, M.A.; Bonomo, R.A. Carbapenems: Past, present, and future. *Antimicrob. Agents Chemother.* 2011, 55, 4943–4960. [CrossRef]

8. Watkins, R.R.; Bonomo, R.A. Increasing prevalence of carbapenem-resistant *Enterobacteriaceae* and strategies to avert a looming crisis. *Expert Rev. Anti Infect. Ther.* 2013, 11, 543–554. [CrossRef]

9. Ghai, I.; Ghai, S. Understanding antibiotic resistance via outer membrane permeability. *Infect. Drug Resist.* 2018, 11, 523–530. [CrossRef]

10. Tran, Q.T.; Williams, S.; Farid, R.; Erdemli, G.; Pearlstein, R. The translocation kinetics of antibiotics through porin OmpC: Insights from structure-based solvation mapping using WaterMap. *Proteins* 2013, 81, 291–299. [CrossRef]

11. Tångdén, T.; Adler, M.; Cars, O.; Sandegren, L.; Löwdin, E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing *Escherichia coli* during exposure to ertapenem in an in vitro pharmacokinetic model. *J. Antimicrob. Chemother.* 2013, 68, 1319–1326. [CrossRef]

12. Forsberg, K.J.; Reyes, A.; Wang, B.; Selleck, E.M.; Sommer, M.O.; Dantas, G. The shared antibiotic resistome of soil bacteria and human pathogens. *Science* 2012, 337, 1107–1111. [CrossRef] [PubMed]

13. Partridge, S.R.; Kwong, S.M.; Firth, N.; Jensen, S.O. Mobile Genetic Elements Associated with Antimicrobial Resistance. *Clin. Microbiol. Rev.* 2018, 31, e00088-17. [CrossRef] [PubMed]

14. Abdi, S.N.; Ghotaslou, R.; Ganbarov, K.; Mobed, A.; Tanomand, A.; Yousefi, M.; Asgharzadeh, M.; Kafil, H.S. *Acinetobacter baumannii* Efflux Pumps and Antibiotic Resistance. *Infect. Drug Resist.* 2020, 13, 423–434. [CrossRef]

15. Pérez-Varela, M.; Corral, J.; Aranda, J.; Barbé, J. Roles of Efflux Pumps from Different Super-families in the Surface-Associated Motility and Virulence of Acinetobacter baumannii ATCC 17978. *Antimicrob. Agents Chemother.* 2019, 63, e02190-18. [CrossRef] [PubMed]

16. Xu, C.; Bilya, S.; Xu, W. adeABC efflux gene in Acinetobacter baumannii. *New Microbes New Infect.* 2019, 30, 100549. [CrossRef] [PubMed]

17. Shen, J.; Wang, Y.; Schwarz, S. Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. *J. Antimicrob. Chemother.* 2013, 68, 1697–1706. [CrossRef]

18. Kaminoshida, G.; Akaji, T.; Takemoto, N.; Suzuki, Y.; Sato, Y.; Kai, D.; Hibino, T.; Yamaguchi, D.; Kikuchi-Ueda, T.; Nishida, S.; et al. Lipopolysaccharide-Deficient Acinetobacter baumannii Due to Colistin Resistance Is Killed by Neutrophil-Produced Lysozyme. *Front. Microbiol.* 2020, 11, 573. [CrossRef]
19. Chen, L.; Tan, P.; Zeng, J.; Yu, X.; Cai, Y.; Liao, K.; Guo, P.; Chen, Y.; Wu, Z.; Qu, P.; et al. Impact of an Intervention to Control Imipenem-Resistant Acinetobacter baumannii and Its Resistance Mechanisms: An 8-Year Survey. *Front. Microbiol.* 2021, 11, 610109. [CrossRef]

20. Vetting, M.W.; Hegde, S.S.; Wang, M.; Jacoby, G.A.; Hooper, D.C.; Blanchard, J.S. Structure of QnrB1, a plasmid-mediated fluoroquinolone resistance factor. *J. Biol. Chem.* 2011, 286, 25265–25273. [CrossRef]

21. Unemo, M.; Golparian, D.; Nicholas, R.; Ohnishi, M.; Gallay, A.; Sedaoui, P. High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure. *Antimicrob. Agents Chemother.* 2012, 56, 1273–1280. [CrossRef]

22. Garcia, M.M. Carbapenemases: A real threat. *APUA Newsfl.* 2013, 31, 4–6.

23. Birnbaum, J.; Kahn, F.M.; Kropp, H.; Macdonald, J.S. Carbapenems, a new class of beta-lactam antibiotics: Discovery and development of imipenem/cilastatin. *Am. J. Med.* 1985, 78, 3–21. [CrossRef]

24. Kattan, J.N.; Villegas, M.V.; Quinn, J.P. New developments in carbapenems. *Clin. Microbiol. Infect.* 2008, 14, 1102–1111. [CrossRef] [PubMed]

25. Thyrum, P.T.; Yeh, C.; Birmingham, B.; Lasseter, K. Pharmacokinetics of Meropenem in Patients with Liver Disease. *Clin. Infect. Dis.* 1997, 24, S184–S190. [CrossRef] [PubMed]

26. Schwaber, M.J.; Carmeli, Y. Carbapenem-resistant *Enterobacteriaceae*: A potential threat. *J. Am. Med. Assoc.* 2008, 300, 2911–2913.

27. Nordmann, P.; Naas, T.; Poirel, L. Global spread of carbapenemase-producing *Enterobacteriaceae*. *Emerg. Infect. Dis.* 2011, 17, 1791–1798. [CrossRef]

28. Potron, A.; Poirel, L.; Nordmann, P. Emerging broad-spectrum resistance to Pseudo-monas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. *Int. J. Antimicrob. Agents* 2015, 45, 568–585. [CrossRef]

29. Queenan, A.M.; Bush, K. Carbapenemases: The Versatile beta-Lactamases. *Clin. Microbiol. Rev.* 2007, 20, 440–458. [CrossRef]

30. Queenan, A.M.; Shang, W.; Flamm, R.; Bush, K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. *Antimicrob. Agents Chemother.* 2010, 54, 565–569. [CrossRef]

31. Tzouvelekis, L.S.; Markogiannakis, A.; Psychogiou, M.; Tassios, P.; Daikos, G.L. Carbapenemases in Klebsiella pneumoniae and other *Enterobacteriaceae*: An evolving crisis of global dimensions. *Clin. Microbiol. Rev.* 2012, 25, 682–707. [CrossRef]

32. Yigit, H.; Queenan, A.M.; Anderson, G.J.; Domenech-Sanchez, A.; Biddle, J.W.; Steward, C.D.; Alberti, S.; Bush, K.; Tenover, F.C. Novel Carbapenem-Hydrolyzing beta-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae. *Antimicrob. Agents Chemother.* 2001, 45, 1151–1161. [CrossRef] [PubMed]

33. Deshpande, L.M.; Jones, R.N.; Fritsche, T.R.; Sader, H.S. Occurrence and characterization of carbapenemase-producing *Enterobacteriaceae*: Report from the SENTRY Antimicrobial Surveillance Program (2000–2004). *Microb. Drug Resist.* 2006, 12, 223–230. [CrossRef] [PubMed]

34. Qi, Y.; Wei, Z.; Ji, S.; Du, X.; Shen, P.; Yu, Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. *J. Antimicrob. Chemother.* 2010, 66, 307–312. [CrossRef]

35. Leavitt, A.; Chmelinsky, I.; Carmeli, Y.; Navon-Venezia, S. Complete Nucleotide Sequence of KPC-3-Encoding Plasmid pKpQIL in the Epidemic Klebsiella pneumoniae Sequence Type 258. *Antimicrob. Agents Chemother.* 2011, 54, 4493–4496. [CrossRef]

36. Woodford, N.; Tierno, P.M., Jr.; Young, K.; Tysall, L.; Palepou, M.F.; Ward, E.; Painter, R.E.; Suber, D.F.; Shungu, D.; Silver, L.L. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. *Antimicrob. Agents Chemother.* 2004, 48, 4793–4799. [CrossRef] [PubMed]

37. Woodford, N.; Zhang, J.; Warner, M.; Kaufmann, M.E.; Matos, J.; Macdonald, A.; Brudney, D.; Sompo-linsky, D.; Navon-Venezia, S.; Livermore, D.M. Arrival of Klebsiella pneumoniae producing carbapenemase in the United Kingdom. *J. Antimicrob. Chemother.* 2008, 68, 1261–1264.

38. Walthier-Rasmussen, J.; Heiby, N. Class A carbapenemases. *J. Antimicrob. Chemother.* 2007, 60, 470–482. [CrossRef]

39. Moquet, O.; Bouchiat, C.; Kinana, A.; Seck, A.; Arouna, O.; Bercion, R.; Breurec, S.; Garin, B. Class D OXA-48 carbapenemase in multidrug-resistant enterobacteria, Senegal. *Emerg. Infect. Dis.* 2011, 17, 143–144. [CrossRef]

40. Cuzon, G.; Naas, T.; Truong, H.; Villegas, M.V.; Wisell, K.T.; Carmeli, Y. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. *Emerg. Infect. Dis.* 2010, 16, 1349–1356. [CrossRef]

41. Meletis, G. Carbapenem resistance: Overview of the problem and future perspectives. *Ther. Adv. Infect. Dis.* 2016, 3, 15–21. [CrossRef]

42. Aurilio, C.; Sansone, P.; Paladini, A.; Barbarisi, M.; Coppolino, F.; Pota, V.; Pace, M.C. Multidrug Resistance Prevalence in COVID Area. *Life* 2021, 11, 601. [CrossRef] [PubMed]

43. Giurazza, R.; Mazza, M.C.; Andini, R.; Sansone, P.; Pace, M.C.; Durante-Mangoni, E. Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. *Life* 2021, 11, 519. [CrossRef] [PubMed]